BTIG reiterates Buy on Perspective Therapeutics stock after data
BTIG reiterated a Buy rating and $14.00 price target on Perspective Therapeutics (NYSE: CATX) after data presentation. The stock fell 26% to $1.61 following mixed results, but BTIG sees the sell-off as excessive. Other analysts have mixed views, with some downgrading and others initiating coverage with positive ratings. The company's VMT-α-NET program shows promising results compared to Lutathera.
How this was made
The 30-second read
Why it matters
Analyst coverage upgrades and price target changes reflect belief that the market over‑reacted to modest efficacy dip.
Market read
New clinical data could drive short‑term price rebound for CATX.
What to watch
Phase‑3 design uncertainty and funding needs may limit upside.
Background
Perspective Therapeutics presented its largest VMT‑α‑NET dataset at ESMO, prompting analyst coverage updates.
Ticker impact
BTIG reiterates Buy on Perspective Therapeutics after presentation of new VMT-α-NET trial data showing 33% ORR in cohort 2 and higher response in cohort 3.
likely upside as investors price in the improved efficacy signals
Analyst cites oversold RSI and compares ORR favorably to Lutathera, suggesting market may rebound.
Market effects
Positive signal for radiopharmaceutical and lead‑212 platform companies.
U.S. biotech sector may see modest lift.
Limited to niche oncology therapeutic space.
Counterpoint
The drop in ORR for cohort 2 and safety concerns could still weigh on the stock.
Key entities
- companyPerspective Therapeutics Inc.
Developer of lead‑212 radiopharmaceuticals.
- analyst_firmBTIG
Reiterated Buy rating and $14 price target.
